{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:44Z","timestamp":1791670304439,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115266","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:57:58Z","timestamp":1738209478000},"page":"115266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-0237","authenticated-orcid":false,"given":"Fabian","family":"Acker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7018-2856","authenticated-orcid":false,"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Heinzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Rost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Aguinarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-5516","authenticated-orcid":false,"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-7741","authenticated-orcid":false,"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike C.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115266_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ejca.2025.115266_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the tnm stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115266_bib3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs concurrent chemoradiation for stage III non\u2013small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2025.115266_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115266_bib5","first-page":"990","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"380","author":"Antonia","year":"2019","journal-title":"Reply N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2025.115266_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the pacific trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115266_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115266_bib8","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non\u2013small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115266_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir Invest"},{"key":"10.1016\/j.ejca.2025.115266_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586449","article-title":"Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer-cross-sectional study of eligibility and administration rates","volume":"10","author":"Eichkorn","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115266_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined radiotherapy and anti\u2013PD-L1 antibody synergistically enhances antitumor effect in non\u2013small cell lung cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115266_bib12","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2025.115266_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy\u2013immunotherapy combinations \u2013 perspectives and challenges","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2025.115266_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.115266_bib15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-23-2568","article-title":"Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage iii non-small cell lung cancer: TORG1937 (DATE Study)","volume":"30","author":"Nakamichi","year":"2024","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115266_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.ejca.2025.115266_bib17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiologyA proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2025.115266_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115266_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamaoncol.2019.6731","article-title":"Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial","volume":"6","author":"Jabbour","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115266_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer Amst Neth"},{"issue":"2","key":"10.1016\/j.ejca.2025.115266_bib21","first-page":"248","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2025.115266_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115266_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115266_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2022.10.006","article-title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: the phase II DETERRED trial","volume":"174","author":"Liu","year":"2022","journal-title":"Lung Cancer Amst Neth"},{"issue":"4","key":"10.1016\/j.ejca.2025.115266_bib25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ijrobp.2023.01.006","article-title":"Dose-limiting pulmonary toxicity in a phase 1\/2 study of radiation and chemotherapy with ipilimumab followed by nivolumab for patients with stage 3 unresectable non-small cell lung cancer","volume":"116","author":"Liveringhouse","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2025.115266_bib26","article-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: results from the phase 1 CLOVER study","volume":"190","author":"Kim","year":"2024","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ejca.2025.115266_bib27","first-page":"1","volume":"9","author":"Bradley","year":"2024"},{"issue":"16_","key":"10.1016\/j.ejca.2025.115266_bib28","article-title":"Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study","volume":"41","author":"Teng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115266_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.8057","article-title":"Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non\u2013small-cell lung cancer (NSCLC): From KEYNOTE-799","volume":"42","author":"Reck","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115266_bib30","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115266_bib31","doi-asserted-by":"crossref","first-page":"TPS8584","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8584","article-title":"Randomized phase III trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: a trial of the ECOG-ACRIN Cancer Research Group (EA5181)","volume":"39","author":"Varlotto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115266_bib32","unstructured":"Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial. May 10, 2024. Accessed August 9, 2024. https:\/\/news.bms.com\/news\/details\/2024\/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-CheckMate--73L-Trial\/default.aspx."},{"issue":"2","key":"10.1016\/j.ejca.2025.115266_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115266_bib34","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115266_bib35","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115266_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115266_bib37","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"issue":"10274","key":"10.1016\/j.ejca.2025.115266_bib38","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2025.115266_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:39:11Z","timestamp":1777351151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"alternative-id":["S0959804925000474"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115266","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115266"}}